Cassava Sciences Inc (SAVA)

[polarbear77]

https://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/


Dr Afshar may disagree with your biased negativity. After 148 weeks for the therapeutic high-dose participants they maintained (on average) their baseline readings (some improved and some declined); but overall a significant improvement over current standard of care’s expected declines.


By all means, please read the above announcement; same was presented at Ctad. Do we expect that a low dose is going to produce those types of results, or a therapeutic high dose? Pain subsides with 10mg of ibuprofen or 600mg?


Seems common sense to me; dose-dependent cognitive improvement is what the outside experts and the company are telling us.


Pick your chart line if you’re a recently diagnosed AD patient: you’re going with standard of care decline or high therapeutic dose of 2-73?


YMMV, I’m not a scientist, all can do their own reading and DD.